iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2

Ali, Zahir; Aman, Rashid; Mahas, Ahmed; Rao, Gundra Sivakrishna; Tehseen, Muhammad; Maršić, Tin; Salunke, Rahul; Subudhi, Amit Kumar; Hala, Sharif; Hamdan, Samir M.; Pain, Arnab; Alofi, Fadwa S.; Alsomali, Afrah; Hashem, Anwar M.; Khogeer, Asim; Almontashiri, Naif A M; Abedalthagafi, Malak; Hassan, Norhan; Mahfouz, Magdy M.

doi:10.1016/j.virusres.2020.198129

Cited by 247 publications

(246 citation statements)

References 49 publications

(88 reference statements)

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…1 b). For instance, Ali et al, (2020) designed their primers and crRNAs targeting N and E genes of the SARS-CoV-2 genome. To test the performance of their system, they considered 21 positive samples with qPCR.…”

Section: Cas12-based Sars-cov-2 Detectionmentioning

confidence: 99%

“…For the RNA targets such as SARS-CoV-2, an additional step of RT should be performed before the application process. So far, most studies utilized isothermal amplification methods such as RT-LAMP ( Ali et al, 2020 ; Broughton et al, 2020 ), RT-RPA ( Ding et al, 2020 ; Lucia et al, 2020 ), and RT-RAA ( Guo et al, 2020 ) for their Cas12-based assays. Utilization of isothermal amplification methods eliminates the need for a thermal cycler and increases the suitability of the assay for point-of-care (POC) applications.…”

Section: Cas12-based Sars-cov-2 Detectionmentioning

confidence: 99%

See 1 more Smart Citation

CRISPR-based detection of SARS-CoV-2: A review from sample to result

Nouri

Tang

Dong

et al. 2021

Biosensors and Bioelectronics

105

View full text Add to dashboard Cite

Section: Cas12-based Sars-cov-2 Detectionmentioning

confidence: 99%

Section: Cas12-based Sars-cov-2 Detectionmentioning

confidence: 99%

CRISPR-based detection of SARS-CoV-2: A review from sample to result

Nouri

Tang

Dong

et al. 2021

Biosensors and Bioelectronics

105

View full text Add to dashboard Cite

“…[37] with permission These steps involve bulky equipment and are not suitable for POC use. Other recent reports have demonstrated the utility of CRISPR-Cas for COVID-19 diagnostics in clinical samples [45][46][47]. However, RNA extraction is performed manually, proving to a critical limitation to its POC use.…”

Section: Crispr-based Diagnosticsmentioning

confidence: 99%

SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations

et al. 2020

View full text Add to dashboard Cite

The unprecedented global pandemic known as SARS-CoV-2 has exercised to its limits nearly all aspects of modern viral diagnostics. In doing so, it has illuminated both the advantages and limitations of current technologies. Tremendous effort has been put forth to expand our capacity to diagnose this deadly virus. In this work, we put forth key observations in the functionality of current methods for SARS-CoV-2 diagnostic testing. These methods include nucleic acid amplification-, CRISPR-, sequencing-, antigen-, and antibody-based detection methods. Additionally, we include analysis of equally critical aspects of COVID-19 diagnostics, including sample collection and preparation, testing models, and commercial response. We emphasize the integrated nature of assays, wherein issues in sample collection and preparation could impact the overall performance in a clinical setting.

show abstract

“…This assay is capable of carrying out reverse transcription and LAMP simultaneously (20–30 min), followed by virus DNA detection using Cas12 (10 min) [ 104 ]. Likewise, another platform, in vitro specific CRISPR-based assay for nucleic acid detection (iSCAN), has been proposed, which coupled RT-LAMP with CRISPR-Cas12 for rapid (less than one hour) detection of SARS-CoV-2 [ 106 ].…”

Section: Covid-19 Detection At Poc Levelmentioning

confidence: 99%

Point of Care Diagnostics in the Age of COVID-19

et al. 2020

View full text Add to dashboard Cite

The recent outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated serious respiratory disease, coronavirus disease 2019 (COVID-19), poses a major threat to global public health. Owing to the lack of vaccine and effective treatments, many countries have been overwhelmed with an exponential spread of the virus and surge in the number of confirmed COVID-19 cases. Current standard diagnostic methods are inadequate for widespread testing as they suffer from prolonged turn-around times (>12 h) and mostly rely on high-biosafety-level laboratories and well-trained technicians. Point-of-care (POC) tests have the potential to vastly improve healthcare in several ways, ranging from enabling earlier detection and easier monitoring of disease to reaching remote populations. In recent years, the field of POC diagnostics has improved markedly with the advent of micro- and nanotechnologies. Due to the COVID-19 pandemic, POC technologies have been rapidly innovated to address key limitations faced in existing standard diagnostic methods. This review summarizes and compares the latest available POC immunoassay, nucleic acid-based and clustered regularly interspaced short palindromic repeats- (CRISPR)-mediated tests for SARS-CoV-2 detection that we anticipate aiding healthcare facilities to control virus infection and prevent subsequent spread.

show abstract

iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2

Cited by 247 publications

References 49 publications

CRISPR-based detection of SARS-CoV-2: A review from sample to result

CRISPR-based detection of SARS-CoV-2: A review from sample to result

SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations

Point of Care Diagnostics in the Age of COVID-19

Contact Info

Product

Resources

About